Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 421

1.

Phosphodiesterase-5 inhibitors for the treatment of Raynaud's: a novel indication.

De LaVega AJ, Derk CT.

Expert Opin Investig Drugs. 2009 Jan;18(1):23-9. doi: 10.1517/13543780802525100 . Review.

PMID:
19053879
2.

Phosphodiesterase inhibitors in Raynaud's phenomenon.

Levien TL.

Ann Pharmacother. 2006 Jul-Aug;40(7-8):1388-93. Epub 2006 Jul 11. Review.

PMID:
16835313
3.

Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease.

Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S.

Arch Intern Med. 2006 Jan 23;166(2):231-3.

PMID:
16432094
4.

[Novel indications for phosphodiesterase type 5 inhibitors].

Rosenkranz S, Caglayan E, Erdmann E.

Med Klin (Munich). 2007 Aug 15;102(8):617-30. Review. German.

PMID:
17694282
5.

Understanding, assessing and treating Raynaud's phenomenon.

Boin F, Wigley FM.

Curr Opin Rheumatol. 2005 Nov;17(6):752-60. Review.

PMID:
16224254
6.

Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.

Rosato E, Letizia C, Proietti M, Aversa A, Menghi G, Rossi C, Torella E, Cotesta D, Petramala L, Bruzziches R, Spera G, Pisarri S, Salsano F.

J Biol Regul Homeost Agents. 2009 Jan-Mar;23(1):23-9.

PMID:
19321043
7.

The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon.

Friedman EA, Harris PA, Wood AJ, Stein CM, Kurnik D.

Clin Pharmacol Ther. 2007 Apr;81(4):503-9. Epub 2007 Feb 14.

PMID:
17301734
8.

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.

Fries R, Shariat K, von Wilmowsky H, Böhm M.

Circulation. 2005 Nov 8;112(19):2980-5.

9.

Current drug therapy for scleroderma and secondary Raynaud's phenomenon: evidence-based review.

Henness S, Wigley FM.

Curr Opin Rheumatol. 2007 Nov;19(6):611-8. Review.

PMID:
17917543
10.
11.

Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.

Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR.

J Rheumatol. 2009 Oct;36(10):2264-8. doi: 10.3899/jrheum.090270. Epub 2009 Sep 15.

PMID:
19755613
12.

[Evidence-based therapy of Raynaud's syndrome].

Distler M, Distler J, Ciurea A, Kyburz D, Müller-Ladner U, Reich K, Distler O.

Z Rheumatol. 2006 Jul;65(4):285-9. Review. German.

PMID:
16804699
13.

Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine.

Coleiro B, Marshall SE, Denton CP, Howell K, Blann A, Welsh KI, Black CM.

Rheumatology (Oxford). 2001 Sep;40(9):1038-43.

PMID:
11561116
14.

Raynaud's phenomenon.

Gayraud M.

Joint Bone Spine. 2007 Jan;74(1):e1-8. Epub 2006 Dec 4. Review.

PMID:
17218139
15.

Objective relief of vasospasm by glyceryl trinitrate in secondary Raynaud's phenomenon.

Coppock JS, Hardman JM, Bacon PA, Woods KL, Kendall MJ.

Postgrad Med J. 1986 Jan;62(723):15-8.

16.

Novel phosphodiesterase-5 inhibitors: current indications and future directions.

Sharma R.

Indian J Med Sci. 2007 Dec;61(12):667-79. Review.

PMID:
18174638
17.

Angiotensin converting enzyme inhibitors in Raynaud's phenomenon.

Challenor VF.

Drugs. 1994 Dec;48(6):864-7. Review.

PMID:
7533694
18.

Use of tadalafil in a patient with a secondary Raynaud's phenomenon not responding to sildenafil.

Baumhaekel M, Scheffler P, Boehm M.

Microvasc Res. 2005 May;69(3):178-9.

PMID:
15896360
19.

Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers.

Smith CR, Rodeheffer RJ.

Am J Cardiol. 1985 Jan 25;55(3):154B-157B. Review.

PMID:
3881908
20.

Office evaluation and treatment of Raynaud's phenomenon.

Bolster MB, Maricq HR, Leff RL.

Cleve Clin J Med. 1995 Jan-Feb;62(1):51-61. Review.

PMID:
7859402

Supplemental Content

Support Center